Why Johnson & Johnson (JNJ) Stock Is Up Today

Johnson & Johnson (JNJ) is up 3.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears to be driven mainly by enthusiasm around Johnson & Johnson’s recent U.S. regulatory win for its OTTAVA robotic surgical system, which strengthens the company’s MedTech growth story. Ongoing support may also be coming from the company’s strong second-quarter results and higher 2026 outlook, which gave investors another reason to lean into the stock.

Details:

Johnson & Johnson recently announced U.S. FDA De Novo authorization for the OTTAVA robotic surgical system, clearing it for multiple general surgery procedures in the upper abdomen.

The company has positioned OTTAVA as a table-integrated platform intended to use less operating-room space and help streamline hospital workflows, which could improve its competitive position in surgical robotics.

In its second-quarter 2026 update, Johnson & Johnson reported sales growth to $25.3 billion and raised its full-year 2026 revenue and adjusted earnings guidance.

The recent sequence of regulatory progress in MedTech and improved financial guidance likely reinforced the view that the business has multiple drivers beyond its traditional pharmaceutical portfolio.

Sources:

Johnson & Johnson, SEC, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$JNJ Insider Trading Activity

$JNJ insiders have traded $JNJ stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.

Here’s a breakdown of recent trading of $JNJ stock by insiders over the last 6 months:

JOAQUIN DUATO (CEO and Chairman of the Board) has made 0 purchases and 4 sales selling 171,771 shares for an estimated $44,714,937.
JOSEPH J WOLK (Exec VP, CFO) has made 0 purchases and 4 sales selling 89,654 shares for an estimated $21,767,826.
JOHN C REED (EVP, Innovative Medicine, R&D) has made 0 purchases and 3 sales selling 53,931 shares for an estimated $13,105,233.
VANESSA BROADHURST (EVP, Global Corp Affairs) has made 0 purchases and 2 sales selling 29,251 shares for an estimated $7,300,974.
TIMOTHY SCHMID (EVP, WW Chair, MedTech) has made 0 purchases and 3 sales selling 23,945 shares for an estimated $5,852,268.
JAMES D. SWANSON (EVP, CIO) sold 20,521 shares for an estimated $4,980,446
ELIZABETH FORMINARD (EVP, Chief Legal Officer) has made 0 purchases and 2 sales selling 15,918 shares for an estimated $4,090,959.
KATHRYN E WENGEL (EVP, Chief TO and Risk Officer) sold 10,000 shares for an estimated $2,411,500
ROBERT J DECKER (VP Corporate Controller) sold 4,075 shares for an estimated $1,010,070

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$JNJ Hedge Fund Activity

We have seen 2,234 institutional investors add shares of $JNJ stock to their portfolio, and 2,155 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 58,301,609 shares (+inf%) to their portfolio in Q2 2026, for an estimated $14,806,859,637
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 19,126,165 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,857,472,125
GQG PARTNERS LLC removed 7,292,131 shares (-99.7%) from their portfolio in Q2 2026, for an estimated $1,851,982,510
PRICE T ROWE ASSOCIATES INC /MD/ added 6,505,745 shares (+39.4%) to their portfolio in Q2 2026, for an estimated $1,652,264,057
DIAMANT ASSET MANAGEMENT, INC. removed 4,454,805 shares (-99.6%) from their portfolio in Q2 2026, for an estimated $1,131,386,825
FISHER ASSET MANAGEMENT, LLC added 4,043,445 shares (+43.6%) to their portfolio in Q2 2026, for an estimated $1,026,913,726
CAPITAL WORLD INVESTORS added 3,465,654 shares (+29.5%) to their portfolio in Q2 2026, for an estimated $880,172,146

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$JNJ Government Contracts

We have seen $36,776,998 of award payments to $JNJ over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

4569579217!4.5MM LCP PROXIMAL FEMUR: $471,086
4571008411!3.5 VOLT(TM) STRAIGHT PLATE 18H/L241MM: $371,238
4570981518!VA LOCKING HAND INSTRUMENT: $271,776
4569393992!CSS+ LARGE SET: $218,394
4569589297!3.5/4.0 IMPLANT & INST SET: $210,632

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$JNJ Congressional Stock Trading

Members of Congress have traded $JNJ stock 11 times in the past 6 months. Of those trades, 4 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $JNJ stock by members of Congress over the last 6 months:

REPRESENTATIVE RICHARD MCCORMICK has traded it 3 times. They made 0 purchases and 3 sales worth up to $45,000 on 07/30, 03/19.
REPRESENTATIVE THOMAS H. KEAN, JR. has traded it 3 times. They made 0 purchases and 3 sales worth up to $45,000 on 06/29, 06/02, 03/26.
REPRESENTATIVE LLOYD DOGGETT has traded it 2 times. They made 2 purchases worth up to $30,000 on 06/09, 03/10 and 0 sales.
SENATOR ALAN ARMSTRONG has traded it 2 times. They made 2 purchases worth up to $65,000 on 03/30, 03/27 and 0 sales.
SENATOR JOHN BOOZMAN sold up to $15,000 on 03/19.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$JNJ Price Targets

Multiple analysts have issued price targets for $JNJ recently. We have seen 11 analysts offer price targets for $JNJ in the last 6 months, with a median target of $263.0.

Here are some recent targets:

Joanne Wuensch from Citigroup set a target price of $298.0 on 07/08/2026
Terence Flynn from Morgan Stanley set a target price of $284.0 on 07/08/2026
Vamil Divan from Guggenheim set a target price of $270.0 on 06/26/2026
David Risinger from Leerink Partners set a target price of $265.0 on 05/13/2026
Larry Biegelsen from Wells Fargo set a target price of $263.0 on 04/15/2026
Rick Wise from Stifel set a target price of $250.0 on 04/15/2026
Matt Miksic from Barclays set a target price of $255.0 on 04/15/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.